Be smarter and faster with PRO Alerts on OCAT
- Advanced Cell Technology has published unprecedented clinical data for dry AMD trials.
- The company has positioned itself with a strong cash runway through 2017 and beyond.
- Twenty million dollars currently available through the existing Lincoln Park financing facility.
- Current financing facility can be secured at the market pricing.
- For the first time, ACTC has been invited to a top-tier Wall Street conference at a Piper Jaffray-sponsored event.
- Efficacy gains are much more likely to persist for stem cell trials than for drug trials.
- The worldwide age-related macular degeneration patient population is approximately 200 million. This presents as a $2 trillion market opportunity for a cure.
- In the summer of 2015, ACT's stock should begin an exponential rise, as the company’s trials progress toward commercialization.
Time To Sell Advanced Cell Technology And Buy StemCells, Inc.
- Advanced Cell Technology reports trial results that provide the first evidence of safety, graft survival, and possible biological activity of pluripotent stem cell progeny in individuals with any disease.
- Results should be sufficient to propel Advanced Cell Technology into a well designed Phase II study for SMD and AMD. Declarations of efficacy from the therapy, however, are premature.
- Market response was muted due to a $100 million mixed shelf filing and the inconclusive nature of the results.
- Based on comments from a lead investigator, trophic factors could be involved in determining efficacy, which bodes well for one of Advanced Cell Technology's competitors, StemCells, Inc.
Advanced Cell Technology Is Scaling Up Its Blood Program
- ACT can create a universal, inexhaustible, pure, scalable source of blood/platelets.
- ACT says it has a method to cryopreserve platelets.
- ACT has developed a biomimetic microfluidic platelet bioreactor that recapitulates bone marrow and blood vessel microenvironments.
- The US Government is showing an active interest in contracting a study for cryopreserved platelets.
- ACT is actively looking to partner its blood/platelet program.
Advanced Cell Technology Has Groundbreaking Results
- ACT's Lancet article shows visual acuity in majority of patients.
- Results from Lancet are better than expected.
- Pivotal trial for SMD and AMD is now a real possibility.
- ACT plans to up-list and to move to Phase II this year.
- A joint venture in Phase II is likely.
Update: Advanced Cell Technology Interim Results And Shelf Offerings
- ACTC has published interim results.
- The company has also filed TWO shelf offerings.
- This represents step 4 of my 7 step process for the company.
- Future steps and prospects are discussed.
- Advanced Cell Technology has made great strides, especially in the last several months.
- ACT plans on "rebranding" itself thus breaking ties with its negative financial past.
- The reverse split, NASDAQ up listing, and institutional financing are said to be a linked set of activities.
- ACT continues to add to their industry leading patent portfolio.
- ACT plans to up list to NASDAQ and move to Phase II this year.
Advanced Cell Technology And Dilution: Do We Really Have A Rational Choice?
- Advanced Cell Technology completed a 1:100 reverse split on August 27th, 2014.
- Since the reverse split, there has been no further company news material to a NASDAQ uplisting.
- Given current information, there will be no NASDAQ uplist until after Nov. 12, 2014.
- A reverse split with a proxy for dilution, without the ability to uplist, is usually bad juju, and this is why shareholders are concerned.
A Repudiation Of Advanced Cell Technology's 'Whisper' Results
- Expectations appear extremely high for Interim Phase I results.
- Based on prior studies, cataract surgery could have a substantial affect on visual acuity in Dry AMD patients over time.
- The market may be setting up for a let down when actual results are reported.
Advanced Cell Technology Annual Meeting Announcement: A Harbinger Of...?
- Advanced Cell Technology has scheduled its Annual Meeting.
- The company intends to change its name to Ocata Therapeutics.
- The proposed increase in authorized shares is a harbinger of things to come.
- Advanced Cell Technology has completed a reverse split.
- This is one of the 7 steps which I previously outlined for restoring shareholder value and trust.
- While not fundamentally significant on its own, this event is a harbinger of good things to come.
Advanced Cell Technology: Maximizing Profit On Reverse Splits And Phase I Results
- Uplisting must allow post-publication share price to run and range, before a reverse split.
- A reverse split can affect short- and long-term profits.
- It doesn't matter that Advanced Cell Technology cannot cure some late-stage AMD or SMD patients.
Advanced Cell Technology: Time To Buy The Rumor (Again)
- Advanced Cell Technology appears to be on the eve of reporting interim trial results.
- Expectations are high for positive signs of efficacy for their AMD trial.
- The best approach may be to buy the rumor and sell the news.
- Advanced Cell Technology held a corporate update conference call last night.
- Three new pieces of information were presented.
- All information in the call affirms the process I outlined for rebuilding shareholder value and trust.
- ACT's new management is taking right steps to rebuild shareholder value and trust, but success is far from assured.
- A broad method for quantifying share price in the event of a successful transition to Phase II is discussed.
- The actual inputs to these calculations will depend almost entirely on the details presented in the publication of the company's Phase I results.
- ACT has just scheduled a conference call for Monday in order to provide a "corporate update".
ACTC: Have The Stars Finally Aligned For A Breakout Year?
- Advanced Cell Technology has told investors that trial data has been presented for peer review.
- A new and respected CEO has been hired to transition the company forward.
- Past litigation and legacy issues have been settled.
- Patient confirmed to have sight restored from 20/400 to 20/40.
The Inflection Point For Stem Cells: An Interview With Advanced Cell Technology's Management
- Long awaited interim clinical trial results not controlled by ACTC but the peer review process of the prestigious scientific journal.
- Ongoing CEO search is not focused on the timing but getting the right person for the job.
- Up-listing to NASDAQ, free of legacy issues, and well capitalized to pursue Phase II is targeted by the end of 2014.
Advanced Cell Technology's Conference Call Recap And Analysis
- Advanced Cell Technology's Phase I trials for macular degeneration continue to progress at a very slow pace.
- Advanced Cell Technology finally clears up legacy issues, but at a substantial cost to the company and shareholders.
- During the conference call, Advanced Cell Technology reiterates its plans to initiate Phase II trials, up-list to Nasdaq, reverse-split, and achieve a large capital raise, all by year-end.
Advanced Cell Technology: A Key Patent Critique (Part II)
- Advanced Cell Technology's key RPE patent claim may open the door for challenges down the road.
- The recent pull back in the stock market and the biotech space in particular is poor timing for Advanced Cell Technology's planned dilutive capital raise.
- Tough love by management will cause short term pain for existing shareholders but will set the foundation for future success.
- Advanced Cell Technology distances itself from its past with new 10-K filing and restatements.
- Advanced Cell Technology's patent review leads to questions and potential concerns.
- Advanced Cell Technology's patent claims vs. the scientific method used in their AMD trial appear contradictory.
Fri, Nov. 7, 9:39 AM
Mon, Oct. 20, 10:43 AM
Wed, Oct. 15, 7:50 AM
- Advanced Cell Technology (OTCQB:ACTC) announces that Phase 1/2 clinical data for the company's Retinal Pigment Epithelium (RPE) cells for the treatment of Stargardt's macular degeneration (SMD) and dry age-related macular degeneration (AMD) has been published online in The Lancet.
- The data from 18 patients with at least six months of post-transplant follow-up show a favorable safety profile. Also, 13 of the 18 patients exhibited increased pigmentation in the RPE layer after transplantation.
- The SMD and AMD clinical trials are designed to assess the safety and tolerability of human embryonic stem cell-derived RPE cells following sub-retinal transplantion into patients at 12 months, the studies' primary endpoint.
- Related ticker: (NASDAQ:STEM)
Tue, Oct. 14, 5:18 PM
Thu, Sep. 25, 10:01 AM
- Advanced Cell Technology (OTCQB:ACTCD -0.3%) reports that the final patient has been treated in the UK-based Phase 1 clinical trial evaluating the safety and tolerability of the company's RPE cell therapy following sub-retinal implantation in patients with Stargardt's macular degeneration (SMD).
- To date, no cell- or immune-related adverse events have been reported in any of the patients.
- The company is working with U.S. and European regulators to commence a Phase 2 trial to assess the safety and efficacy of RPE cell therapy in patients with SMD as well as dry age-related macular degeneration.
Wed, Aug. 27, 5:56 PM
- Going forward, there will be one share of Advanced Cell Technology (OTCQB:ACTC) for every 100 shares that previously existed. CFO/COO Ted Myles says the move is "part of a larger strategy to up-list to a national stock exchange and to raise awareness and visibility with fundamental-based, institutional biotech investors."
- ACTC closed today at $0.08. Nonetheless, its market cap stood at $274.1M.
Thu, Jul. 3, 9:24 AM
- Advanced Cell Technology (ACTC) enters into a $30M common stock purchase agreement with Lincoln Park Capital Fund LLC. Under the terms of the agreement, after the SEC declares its registration statement effective, ACTC will have the right to sell up to $30M worth of common shares to LPC over a 36-month period. The company issued common shares to LPC as payment for its commitment fee.
Tue, Jun. 24, 11:17 AM| 2 Comments
Tue, Jun. 24, 10:04 AM
- Advanced Cell Technology (ACTC +1.2%) hires Paul Wotton, Ph.D., as its President & CEO effective July 21. He joins the company from Antares Pharma where he was also Chief Executive.
- Dr. Wotton will earn a base salary of $575,000 plus a cash incentive bonus of up to $316,250. In additional he will receive options to purchase 30M shares of common stock, stock unit awards equaling 30M shares of common stock and $50,000 for relocation expenses.
- If his employment is terminated without cause or if he quits for good reason, he will receive a lump sum payment equal to his base salary plus unpaid expenses and vacation. If he signs a release of all claims against the company, he will be eligible for an additional lump sum payment equal to a year's salary plus unpaid incentive compensation plus 12 months or COBRA payments plus accelerated vesting of any unvested equity awards that are scheduled to vest within one year of his termination.
- If he is terminated without cause or he quits for good reason within 12 months after a change in control, he will receive a lump sum payment equal to two years' base salary plus unpaid incentive comp plus COBRA plus accelerated vesting of 100% of all outstanding equity incentive awards (contingent on a claims release).
Fri, Jun. 6, 9:21 AM
- Advanced Cell Technology (ACTC) settles the lawsuit brought against the company by Gary Aronson and John Gorton in 2011 claiming the company breached an anti-dilution provision in the warrants held by the two men as a result of certain transactions between the company and other third-party investors.
- Pursuant to the settlement, the company will issue Aronson 269,766,667 shares of ACTC common stock. It will issue Gorton 33,133,333 shares of common stock.
- As compensation for legal fees, it will issue 68,266,667 shares of common stock to the attorneys for Aronson (Herron), 8,533,333 to the attorneys for Gorton (Miller/Steele) and 4,300,000 shares to another attorney that represented both men (Bourke).
Mon, May. 5, 4:33 PM
- Debt holders notify Advanced Cell Technology (ACTC +2.3%) that the remaining principal on the Senior Convertible Notes due June 30, 2015 is immediately due and payable.
- The Note holders notified the company on April 15 that it was in default of the debt due to its failure to deliver shares of common stock issuable to them.
Mon, Apr. 21, 5:38 PM
- Holders of the Senior Secured Convertible Notes due June 30, 2015 send Advanced Cell Technology (ACTC) a notification of default citing the firm's failure to deliver shares of common stock to them within three days of a conversion event. The Event of Default gives the Note holders the right to the immediate repayment of the $1.2M balance.
- The Notes were issued as part of a settlement agreement among the parties consummated on January 11, 2013 whereby the company granted a security interest in virtually all of the company's assets as a condition of the financing.
Mar. 14, 2013, 8:45 AMAdvanced Cell Technology (ACTC.OB) receives approval from an independent Data & Safety Monitoring Board to proceed with the next stage of three stem cell studies in the U.S. and Europe in people with the vision disorders Stargardts Macular Dystrophy and dry age-related macular degeneration. The two trials in the U.S. can include patients with better vision than previously allowed. (PR) | 5 Comments
OCAT vs. ETF Alternatives
Advanced Cell Technology ("ACT"; ACTC), is a biotechnology company developing cellular therapies for treating diseases that impact millions of people worldwide. <br />Helmed by Chairman and CEO Gary Rabin, ACT is currently conducting the only human embryonic stem cell (hESC)-based clinical... More
Other News & PR